BIO-Europe Spring® 2017: Avir BD execs on innovative meds for Canadians

May 5, 2017
Located in Quebec, Canada, Avir Pharma, a specialty pharma company, is part of the Laboratoire Riva group. Its primary focus is to acquire, license or co-develop innovative medicines with an end aim of getting these novel medicines launched and available to Canadian patients. Avir's business development associate, Vanessa Fortin, and VP of business development, Kaled Kadri, chat to Scrip about the company's commercial strategy and key therapy areas of focus. Kadir also discusses reimbursement differences in the Canadian pharmaceutical market and why a business model focused on commercialization, not R&D, works in this region.
Previous Video
BIO-Europe Spring® 2017: Producing monoclonals for at least a tenth of the cost
BIO-Europe Spring® 2017: Producing monoclonals for at least a tenth of the cost

Dutch antibody technology company BiosanaPharma is offering to make monoclonal antibodies at between 5% and...

Next Video
Testimonials highlight opportunities for China cross-border collaboration
Testimonials highlight opportunities for China cross-border collaboration

ChinaBio® Partnering Forum 2017 meets May 31–June 1 in Zhuhai, China. Don’t miss the abundant opportunities...